Threshold Pharmaceuticals, Inc.  

(Public, NASDAQ:THLD)   Watch this stock  
Find more results for Robert L. Tillman
+0.15 (3.42%)
Real-time:   10:07AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.35 - 4.69
52 week 2.58 - 5.58
Open 4.57
Vol / Avg. 280,161.00/631,876.00
Mkt cap 284.89M
P/E     -
Div/yield     -
EPS -0.39
Shares 62.75M
Beta 2.79
Inst. own 57%
Mar 2, 2015
Threshold Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -210.46% -227.41%
Operating margin -207.42% -208.28%
EBITD margin - -196.22%
Return on average assets -38.63% -29.35%
Return on average equity - -
Employees 53 -
CDP Score - -


Suite 300, 170 Harbor Way
United States - Map
+1-650-4748200 (Phone)
+1-650-4742529 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Threshold Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing therapeutic agents that selectively target tumor cells for the treatment of cancer patients. The Company�s lead investigational small molecule, TH-302, is being evaluated in two pivotal Phase III clinical trials and multiple earlier-stage clinical trials. The Company has a global license and co-development agreement for TH-302 with Merck KGaA, with an option to co-commercialize in the United States. As a prodrug, TH-302 is designed to remain essentially inactive in normal tissues, but to activate under conditions of tumor hypoxia. Upon activation, TH-302 releases bromo isophosphoramide mustard (Br-IPM), a potent cytotoxin that kills cells by causing DNA to crosslink. In March 2013, Threshold announced the acquisition of [18F]-HX4 from Siemens Healthcare, to develop [18F]-HX4 to determine a patient�s tumor hypoxia profile.

Officers and directors

Harold E. Selick Ph.D. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Robert L. Simon Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 79
Bio & Compensation  - Reuters
Joel A. Fernandes Vice President - Finance, Controller
Age: 44
Bio & Compensation  - Reuters
Nipun Davar Ph.D. Vice President - Pharmaceutical Development and Manufacturing
Age: 46
Bio & Compensation  - Reuters
Tillman Pearce M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Jeffrey W. Bird M.D., Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 50
Bio & Compensation  - Reuters
David R. Hoffmann Independent Director
Age: 69
Bio & Compensation  - Reuters
Wilfred E. Jaeger M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
George G. C. Parker Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters